Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy

American Journal of Neuroradiology

Volumn 21, Issue 3, 2000, Pages 471-478

  Chow, Kira L ^a   Gobin, Y Pierre ^a   Cloughesy, Timothy ^a   Sayre, James W ^a   Villablanca, J Pablo ^a   Viñuela, Fernando ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; LOBRADIMIL;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRADYKININ; BRAIN; BRAIN NEOPLASMS; CARBOPLATIN; CEREBRAL ANGIOGRAPHY; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; INFUSIONS, INTRA-ARTERIAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0034015832     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Saleman M. Glioblastoma and malignant astrocytoma. In: Kaye A, Laws E, Jr., eds. Brain Tumors: An Encyclopedic Approach. Edinburgh: Churchill Livingstone; 1995; 449-477
2. Shugg D, Allen B. Blizzard L, Dwyer T. Brain cancer incidence, mortality and case survival: observations from two Australian cancer registries. Int J Cancer 1994;59:765-770
3. Greig N, Ries L, Yancik R, Rapoport S. Increasing annual incidence of primary malignant brain tumours in the elderly. J Natl Cancer Inst 1990;82:1621-1624
4. Ahlbom A, Rodvall Y. Brain tumour trends. Lancet 1989;2:1272
5. Wurschmidt F, Bunemann H, Heilmann HP. Prognostic factors in high-grade malignant glioma: a multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol 1995;171:315-321
6. Saleman M. Survival in glioblastoma: historical perspective. Neurosursery 1980;7:435-439
7. Fine H, Dear K, Loeffler J, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-2597
8. Sipos E, Brem H. New delivery systems for brain tumor therapy. Neurologic Clinics 1995;13:813-825
9. Stewart DJ, Belanger JM, Grahovac A, et al. Phase I study of intracarotid administration of carboplatin. Neurosurgery 1992; 30:512-517
10. Dropcho EJ, Rosenfeld SS, Morawetz RB, et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. J Clin Oncol 1992;10:452-458
11. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 1983;52:997-1007
12. Mahaley MJ, Hipp S, EJ D, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989;70:371-378
13. Neuwelt E, Howieson J, Frenkel E, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986;19:573-582
14. Rajan B, Ross C, Lim CC, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 1994:1809-1815
15. Salminen E, Nuutinen JM, Huhtala S. Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 1996:1918-1923
16. Stenning S, Freedman LS, Bleehan NM. Prognostic factors for high grade glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party. J Neuro-Oncol 1990;9:47-55
17. Watne K, Hannisdal E, Nome O, et al. Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery 1992;30:223-227
18. Inamura R, Nomura R, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994;81:752-758
19. Cloughesy TF, Gobin YP, Black KL, et al. Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow. J Neuro-Oncol 1997;35:121-131
20. Pasqualin A, Barone G, Cioffi F, Rosta L, Scienza R, Da Pian R. The relevance of anatomic and hemodynamic factors to a classification of cerebral arteriovenous malformations. Neurosurgery 1991;28:370-379
21. Kirby S, Brothers M, Irish W, et al. Evaluating glioma therapies: modeling treatments and predicting outcomes. J Natl Cancer Inst 1995;87:1884-1888
22. Lote K, Egeland T, Hager B, et al. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997;15:3129-3140
23. Gehan E, Walker M. Prognostic factors for patients with brain tumors. Nat Cancer Inst Monogr 1977;46:189-195
24. Green S, Byar D, Walker M, et al. Comparison of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121-132
25. Hammoud M, Sawaya R, Shi W, Thall P, Leeds N. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 1996;27:65-73
26. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-554
27. Kowulczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997;41:1028-1038
28. Durmaz R, Erken S, Arslantas A, Atasoy MA, Bal C, Tel E. Management of glioblastoma multiforme: with special reference to recurrence. Clin Neurol Neurosurg 1997;99:117-123
29. Mac-Donald DR, Cascino TL, Schold SCJ, Cairncross G. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280
30. Harsh G. Management of recurrent gliomas and meningiomas. In: Kaye A, Laws E, eds. Brain Tumors: An Encyclopedic Approach. Edinburgh: Churchill Livingstone; 1995:413-428
31. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-388
32. Burger P, Heinz E, Shibata T, et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurgery 1988;68:698-704
33. Reeves GI, Marks JE. Prognostic significance of lesion size for glioblastoma multiforme. Radiology 1979;132:469-471
34. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338-343
35. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-388
36. Brem S. The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 1976;23:440-453
37. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;333:1182-1186
38. Russel DC, Rubinstein LJ. Pathology of Tumors of the Nervous System. 5th ed. London: Arnold; 1989
39. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-372
40. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 1998;88:513-520
41. Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 1998; 49:189-196
42. Korkolopoulou P, Christodoulou P, Kouzelis K, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997;75:1269-1278
43. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol 1993;52:609-618
44. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. Cancer 1989;64:2014-2023
45. Kadota T, Nakagawa H, Kuroda C. Malignant glioma: evaluation with 3D time-of-flight MR angiography. Acta Radiol 1998; 39:227-232
46. Less JR, Skallak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Research 1991;51:265-273
47. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Research 1994;54:4564-4568
48. Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992;76:792-798